Transcept Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Richmond CA United States (2001)
Status: Acquired by Paratek Pharmaceuticals Inc (1996) → now Novo Nordisk (2023)

Organization Overview

First Clinical Trial
2006
NCT00380081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Transcept Pharmaceuticals (1) Acquired (2)

calcitriol (rocaltrol) (8 trials)

docetaxel (taxotere) (3 trials)

zolpidem (ambien) (3 trials)

Drugs in Phase 2 Trials (6)

Key: Transcept Pharmaceuticals (1) Acquired (5)

banoxantrone (3 trials)

erlotinib (tarceva) (1 trial)

gemcitabine (gemzar) (1 trial)

naproxen (naprosyn) (1 trial)

ondansetron (zofran) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Phase 1 Trials (1)

zopiclone (Zimovane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Compulsive Personality Disorder (Phase 2)

Disease (Phase 2)

Obsessive-Compulsive Disorder (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 10